tetano
Editor, Senior Moderator
Expert Opin Biol Ther
. 2023 Dec 15.
doi: 10.1080/14712598.2023.2296569. Online ahead of print. Intravenous immunoglobulin as a potential treatment for long COVID
Matthew W McCarthy[SUP] 1 [/SUP]
Affiliations
Introduction: On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health (NIH) opened enrollment for the therapeutic arm of the RECOVER initiative, a prospective, randomized study to evaluate new treatment options for long coronavirus disease 2019 (long COVID).
Areas covered: One of the first drugs to be studied in this nationwide initiative is intravenous immunoglobulin (IVIG), which will be a treatment option for subjects enrolled in RECOVER-AUTO, a randomized trial to investigate therapeutic strategies for autonomic dysfunction related to long COVID.
Expert opinion: IVIG is a mixture of human antibodies (human immunoglobulin) that has been widely used to treat a variety of diseases, including immune thrombocytopenia purpura, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy, and certain infections such as influenza, human immunodeficiency virus, and measles. However, the role of IVIG in the treatment of post-COVID-19 conditions is uncertain. This manuscript examines what is known about IVIG in the treatment of long COVID and explores how this therapeutic agent may be used in the future to address this condition.
Keywords: COVID-19; IVIG; Immunoglobulin; RECOVER; SARS-CoV-2; long COVID.
. 2023 Dec 15.
doi: 10.1080/14712598.2023.2296569. Online ahead of print. Intravenous immunoglobulin as a potential treatment for long COVID
Matthew W McCarthy[SUP] 1 [/SUP]
Affiliations
- PMID: 38100573
- DOI: 10.1080/14712598.2023.2296569
Introduction: On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health (NIH) opened enrollment for the therapeutic arm of the RECOVER initiative, a prospective, randomized study to evaluate new treatment options for long coronavirus disease 2019 (long COVID).
Areas covered: One of the first drugs to be studied in this nationwide initiative is intravenous immunoglobulin (IVIG), which will be a treatment option for subjects enrolled in RECOVER-AUTO, a randomized trial to investigate therapeutic strategies for autonomic dysfunction related to long COVID.
Expert opinion: IVIG is a mixture of human antibodies (human immunoglobulin) that has been widely used to treat a variety of diseases, including immune thrombocytopenia purpura, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy, and certain infections such as influenza, human immunodeficiency virus, and measles. However, the role of IVIG in the treatment of post-COVID-19 conditions is uncertain. This manuscript examines what is known about IVIG in the treatment of long COVID and explores how this therapeutic agent may be used in the future to address this condition.
Keywords: COVID-19; IVIG; Immunoglobulin; RECOVER; SARS-CoV-2; long COVID.